Dr. Kory and Dr. Marik join host Betsy Ashton to talk about the new COVID variants, the ACTIV-6 Trial and provide you with updates to I-RECOVER.
ACTIV-6 severely limited the use of ivermectin, administering a dose below what is known to be effective on the variants at the time and received too late (6 days on average) after the onset of symptoms. Despite these obvious shortfalls, there was a statistically significant, albeit modest, impact on time to clinical recovery for patients using ivermectin to treat COVID-19. T